Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
August 04, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
August 01, 2022 08:00 ET
|
Apexigen
-Common stock of Apexigen to commence trading on the Nasdaq Capital Market today under the ticker symbol “APGN”- -Clinical pipeline includes multiple Phase 2 studies of sotigalimab, a CD40 agonist...
Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination
July 18, 2022 18:42 ET
|
Apexigen
SAN CARLOS, Calif. and NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- On March 18, 2022 Brookline Capital Acquisition Corp. (“BCAC”), a life-science focused Special Purpose Acquisition Company (“SPAC”)...
Apexigen to Participate in the Brookline Capital Markets Newport Symposium
July 11, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
Apexigen Announces Board Appointment and New Chair
June 29, 2022 16:05 ET
|
Apexigen
SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen” or the “Company”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the...
Apexigen Appoints William Duke as Chief Financial Officer
June 08, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy
June 06, 2022 08:00 ET
|
Apexigen
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of...
Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform
May 09, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022
April 12, 2022 16:35 ET
|
Apexigen
-The combination of intratumoral sotigalimab and systemic pembrolizumab induced broad innate and adaptive immune activation in local and distant tumors- -Oral presentation on April 12, 2022 at 3:35...
Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022
April 07, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...